{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:51:38Z","timestamp":1790247098549,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ajog.2020.11.006","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T08:40:16Z","timestamp":1618908016000},"page":"S1126-S1144.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"S","title":["Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"226","author":[{"given":"Monica","family":"Cruz-Lemini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana","family":"Ullmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-6407","authenticated-orcid":false,"given":"Elisa","family":"Llurba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2020.11.006_bib1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0002-9378(98)70160-7","article-title":"Etiology and pathogenesis of preeclampsia: current concepts","volume":"179","author":"Dekker","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1477-7827-2-53","article-title":"The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia","volume":"2","author":"Fisher","year":"2004","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.ajog.2020.11.006_bib3","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1471-0528.2009.02317.x","article-title":"The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort","volume":"116","author":"McDonald","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2020.11.006_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1081\/PRG-100100138","article-title":"Mortality and morbidity associated with early-onset preeclampsia","volume":"19","author":"Murphy","year":"2000","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.ajog.2020.11.006_bib5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.11.006_bib6","first-page":"CD001059","article-title":"Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems","volume":"10","author":"Hofmeyr","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.11.006_bib7","first-page":"CD004227","article-title":"Antioxidants for preventing pre-eclampsia","volume":"2008","author":"Rumbold","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.11.006_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus Placebo in Pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.11.006_bib10","series-title":"Clinical Guidelines hypertension in pregnancy: diagnosis and management","year":"2019"},{"key":"10.1016\/j.ajog.2020.11.006_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0033-1338172","article-title":"Prediction of recurrent preeclampsia using first-trimester uterine artery Doppler","volume":"31","author":"Demers","year":"2014","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2020.11.006_bib12","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1182\/blood-2011-07-319749","article-title":"Is heparin a placental anticoagulant in high-risk pregnancies?","volume":"118","author":"Kingdom","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2020.11.006_bib13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.AOG.0000128902.84876.d4","article-title":"Effects of low-molecular-weight and unfractionated heparin on trophoblast function","volume":"104","author":"Quenby","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000098952","article-title":"Enoxaparin reduces H2O2-induced activation of human endothelial cells by a mechanism involving cell adhesion molecules and nuclear transcription factors","volume":"79","author":"Manduteanu","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.ajog.2020.11.006_bib15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ultrasmedbio.2006.05.030","article-title":"Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension","volume":"32","author":"Torricelli","year":"2006","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.ajog.2020.11.006_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.placenta.2014.12.008","article-title":"Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor","volume":"36","author":"Yinon","year":"2015","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.11.006_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0015-0282(02)03222-3","article-title":"Preventing adverse obstetric outcomes in women with genetic thrombophilia","volume":"78","author":"Grandone","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2020.11.006_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10641950109152640","article-title":"Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias","volume":"20","author":"Kupferminc","year":"2001","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.ajog.2020.11.006_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.11.006_bib20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2013-01-478958","article-title":"Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications","volume":"123","author":"Rodger","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2020.11.006_bib21","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/S0140-6736(16)31139-4","article-title":"Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials","volume":"388","author":"Rodger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.11.006_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000509662","article-title":"Early prophylactic enoxaparin for the prevention of preeclampsia and intrauterine growth restriction: a randomized trial","volume":"47","author":"Llurba","year":"2020","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2020.11.006_bib23","doi-asserted-by":"crossref","first-page":"296.e1","DOI":"10.1016\/j.ajog.2017.01.014","article-title":"Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial","volume":"216","author":"Groom","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/uog.15789","article-title":"Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis","volume":"47","author":"Roberge","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib25","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.11.006_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajog.2020.11.006_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.preghy.2012.11.001","article-title":"The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP)","volume":"3","author":"Tranquilli","year":"2013","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2020.11.006_bib28","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1701-2163(15)30533-8","article-title":"Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary","volume":"36","author":"Magee","year":"2014","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2020.11.006_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000357592","article-title":"Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol","volume":"36","author":"Figueras","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2020.11.006_bib31","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.11.006_bib32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ajog.2020.11.006_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.11.006_bib34","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2020"},{"key":"10.1016\/j.ajog.2020.11.006_bib35","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajog.2020.11.006_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jclinepi.2011.09.012","article-title":"Robust meta-analytic conclusions mandate the provision of prediction intervals in meta-analysis summaries","volume":"65","author":"Graham","year":"2012","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ajog.2020.11.006_bib37","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.11.006_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/01443610802042688","article-title":"Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology","volume":"28","author":"Badawy","year":"2008","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1538-7836.2011.04553.x","article-title":"Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT","volume":"10","author":"de Vries","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1160\/TH10-03-0167","article-title":"Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial","volume":"104","author":"Gris","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib41","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-05-0340","article-title":"Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial","volume":"106","author":"Gris","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib42","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/AOG.0000000000001673","article-title":"Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial","volume":"128","author":"Haddad","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib43","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/14767058.2019.1671348","article-title":"Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation","volume":"33","author":"Karada\u011f","year":"2020","journal-title":"J\u00a0Matern Fetal Neonat Med"},{"key":"10.1016\/j.ajog.2020.11.006_bib44","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2011.04407.x","article-title":"Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial","volume":"9","author":"Kingdom","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib45","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood-2011-11-391383","article-title":"Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial","volume":"119","author":"Martinelli","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2020.11.006_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/01.HYP.0000149950.05182.a3","article-title":"Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women","volume":"45","author":"Mello","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2020.11.006_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1538-7836.2008.03230.x","article-title":"Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial","volume":"7","author":"Rey","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/M14-2062","article-title":"Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme","volume":"162","author":"Schleussner","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2020.11.006_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejogrb.2015.12.011","article-title":"FRUIT Investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT","volume":"197","author":"van Hoorn","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2020.11.006_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","article-title":"Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial","volume":"384","author":"Rodger","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.11.006_bib51","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1000641","article-title":"Aspirin plus heparin or aspirin alone in women with recurrent miscarriage","volume":"362","author":"Kaandorp","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.11.006_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH10-05-0334","article-title":"Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial","volume":"105","author":"Visser","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1160\/TH16-02-0169","article-title":"LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis","volume":"116","author":"Mastrolia","year":"2016","journal-title":"Thromb Haemost"},{"issue":"Suppl2","key":"10.1016\/j.ajog.2020.11.006_bib54","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ajog.2020.11.006_bib55","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/uog.15921","article-title":"Low-dose aspirin plus low-molecular-weight heparin for the prevention of pre-eclampsia: yes, no or maybe","volume":"47","author":"Sotiriadis","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"Suppl","key":"10.1016\/j.ajog.2020.11.006_bib56","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.placenta.2010.11.023","article-title":"Placental and trophoblastic in\u00a0vitro models to study preventive and therapeutic agents for preeclampsia","volume":"32","author":"Orendi","year":"2011","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.11.006_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajog.2004.09.029","article-title":"Heparin and aspirin attenuate placental apoptosis in\u00a0vitro: implications for early pregnancy failure","volume":"192","author":"Bose","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib58","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/AOG.0b013e31823234ad","article-title":"Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function","volume":"118","author":"Han","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib59","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/j.1538-7836.2011.04526.x","article-title":"Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling","volume":"9","author":"Drewlo","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib60","doi-asserted-by":"crossref","first-page":"e85258","DOI":"10.1371\/journal.pone.0085258","article-title":"Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination","volume":"9","author":"Hagmann","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2020.11.006_bib61","doi-asserted-by":"crossref","first-page":"H1008","DOI":"10.1152\/ajpheart.00109.2020","article-title":"Low molecular weight heparin promotes transcription and release of placental growth factor from endothelial cells","volume":"318","author":"McLaughlin","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ajog.2020.11.006_bib62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajog.2016.10.016","article-title":"Antiplatelet therapy before or after 16 weeks\u2019 gestation for preventing preeclampsia: an individual participant data meta-analysis","volume":"216","author":"Meher","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/uog.19077","article-title":"Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl4","key":"10.1016\/j.ajog.2020.11.006_bib65","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.ajog.2015.08.042","article-title":"Why is placentation abnormal in preeclampsia?","volume":"213","author":"Fisher","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0143-4004(80)80012-9","article-title":"Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy","volume":"1","author":"Pijnenborg","year":"1980","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2020.11.006_bib67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/jth.12509","article-title":"Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study","volume":"12","author":"Rodger","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib68","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1538-7836.2012.04773.x","article-title":"Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort","volume":"10","author":"Lykke","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib69","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1055\/s-0037-1616738","article-title":"Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins\u2014dalteparin, enoxaparin and tinzaparin","volume":"86","author":"Ellison","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib70","article-title":"Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study","author":"Hastie","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.11.006_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1160\/TH16-03-0221","article-title":"Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial","volume":"116","author":"Salim","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2020.11.006_bib72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000341712","article-title":"Combined screening for preeclampsia and small for gestational age at 11\u201313 weeks","volume":"33","author":"Poon","year":"2013","journal-title":"Fetal Diagn Ther"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820312886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820312886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:38:48Z","timestamp":1757590728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937820312886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0002937820312886"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2020.11.006","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}